OS Therapies has appointed Kerry Clem as Chief Commercial Officer and Frank Knuettel II as Chief Financial Officer to spearhead the commercial launch of its lead cancer immunotherapy, Herlystic™ (OST-HER2), targeting osteosarcoma. Clem will focus on U.S., U.K., and European market preparations, with regulatory approvals anticipated first from the U.K.'s MHRA, followed by the FDA and EMA. The company is pursuing accelerated regulatory pathways and expects to launch Herlystic initially in the U.S. upon approval. These leadership changes coincide with financial strategies including tax credit benefits and vendor payment delays to support the company’s transition to commercialization and growth.
OS Therapies' recent executive appointments come as 60 out of 100 priced Health-sector US stocks on Pluang rose today. For readers following the health sector, here is Pluang's market snapshot as of Oct 01, 2026 19:31 WIB: XRAY (DENTSPLY SIRONA Inc) rose 2.26% to USD 9.06 with 100% buy order activity, HRTX (Heron Therapeutics Inc) increased 2.07% to USD 0.32 despite 74% sell orders, and INO (Inovio Pharmaceuticals Inc) gained 1.64% to USD 1.24 with a near-even buy/sell split.
An analyst at Truist Financial raised Wells Fargo's price target to $95, suggesting a 20.74% upside from its current price. This optimism is driven by expected strong third-quarter earnings of $1.85 per share and $22.34 billion in revenue, surpassing...
Oklo is developing advanced fast-fission reactors to power future data centers and industrial hubs, aiming to lead in carbon-free energy. Piper Sandler reaffirmed an "Overweight" rating on the stock, reflecting confidence in Oklo's growth prospects. ...
Nike is set to release its quarterly earnings on October 1, 2026, with analysts forecasting an EPS of $0.44 and revenue of $11.32 billion, both down from last year. The company's stock has fallen 80% this year, hitting 13-year lows, reflecting a chal...
Lamb Weston is set to report Q3 earnings with analysts forecasting an EPS of $0.59, down from $0.74 last year, and revenue around $1.65 billion, nearly flat compared to the prior year. The company’s "Focus to Win" strategy has generated over $100 mil...
Cal-Maine Foods reported a $58.6 million net loss and a 42% drop in net sales, driven by lower conventional egg prices. An analyst downgraded the stock to Hold with a $70 price target, reflecting a modest 2.85% upside from current levels. Despite cha...
